The 10 most recent market catalysts affecting $TPST, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Tempest Therapeutics' stock surged significantly after announcing an exclusive option agreement with Hebei Senlang Biotechnology. This deal grants Tempest access to a novel in vivo…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 92
Tempest Therapeutic shares are trading higher after the company announced it has entered into an exclusive option agreement to license Hebei Senlang Biotechnology's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates.
This news is a significant positive for Tempest Therapeutics (TPST) as it signals a strategic expansion into the highly innovative and potentially lucrative CAR-T therapy market. T…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 85
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Tempest Therapeutics (TPST) is experiencing a significant pre-market rally due to its announcement of an exclusive option agreement with Hebei Senlang Biotechnology. This deal gran…
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 95
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why
Tempest Therapeutics (TPST) experienced a massive after-hours rally following the announcement of an exclusive option agreement with Hebei Senlang Biotechnology. This deal grants T…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
Tempest Therapeutic shares are trading higher after the company announced it has entered into an exclusive option agreement to license Hebei Senlang Biotechnology's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates.
This headline represents a major corporate catalyst for Tempest Therapeutics (TPST). The exclusive option to license a CD7-targeted lentiviral vector platform and a portfolio of in…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Tempest Therapeutics Enters Into Exclusive Option Agreement To License Senlang's CD7-Targeted Lentiviral Vector Platform And Portfolio Of In Vivo CAR-T Product Candidates
This headline represents a significant corporate catalyst for Tempest Therapeutics, as it gains access to a novel CD7-targeted lentiviral vector platform and a portfolio of in vivo…
Sep 11, 2026
Corporate Catalyst
Neutral
Impact 60
Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share
Tempest Therapeutics is raising approximately $2.5 million through a private placement of common stock and accompanying warrants. While this infusion of capital is crucial for a cl…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
Tempest Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 8,910,579 Shares Of Common Stock
Tempest Therapeutics filed an 8-K to announce a prospectus for the offer and sale of up to 8,910,579 shares of common stock. This is a standard regulatory filing that precedes a po…
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 85
Tempest Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.
This headline represents a direct corporate catalyst, specifically a negative earnings surprise for Tempest Therapeutics. The 'worse-than-expected' Q2 EPS results are a clear indic…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 92
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Tempest Therapeutics announced its Q2 earnings, reporting a loss of $(0.34) per share, which fell short of the consensus estimate of $(0.30). This miss is significant as it indicat…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.